ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2019) 63 P263 | DOI: 10.1530/endoabs.63.P263

Baseline characteristics of adult patients with growth hormone deficiency (GHD) enrolled in NordiNet® International Outcome Study (IOS): are there variations between countries?

Matthias M Weber1, Alberto Pietropoli2 & Charlotte Höybye3


1University Hospital, Universitätsmedizin Mainz, der Johannes Gutenberg-Universität, Mainz, Germany; 2Novo Nordisk Healthcare AG, Zürich, Switzerland; 3Department of Endocrinology and Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.


Czech Republic background: NordiNet® IOS (NCT00960128), a non-interventional study (2006–2016), assessed the effectiveness and safety of real-life treatment with Norditropin. From 23 countries, 2,321 adults with GHD were included; 971, GH-naïve at baseline, were included in the effectiveness analysis set (EAS). Baseline characteristics in the six largest contributing countries were evaluated.

Methods: Patient information was entered at routine clinic visits by participating physicians. EAS baseline data are presented (Table 1).

Results: Proportionally more females than males were enrolled in France and Czech Republic versus other countries. Patients were older in Sweden, Germany and UK; males were older than females except in France and Czech Republic. Mean baseline IGF-I SDS was below 0 across all countries. Mean GH peak was lower in males than in females and varied across countries. Mean BMI (kg/m2) was >25 across all countries. Average baseline GH dose was lowest in Sweden, highest in UK (females) and lowest in Sweden, highest in France (males).

Table 1
GermanySwedenDenmarkFranceUKCzech Republic
N (% of patients enrolled)389 (40)199 (20)151 (16)72 (7)41 (4)37 (4)
Females (%)444237654654
Age (years)48.1 [14.7]: 50.1 [14.8]49.8 [13.7]: 53.5 [13.6]43.4[13.9]:49.6[13.4]43.3 [11.6]: 38.6 [13.5]46.6 [14.2]:52.1 [13.2]45.4 [9.0]: 42.5 [12.8]
IGF-I SDS–1.25 [1.54]: –1.32 [1.68]–1.05 [1.14]: –0.91 [1.29]–0.55 [1.29]:–0.70 [1.02]–0.71 [1.62]: –0.75 [2.19]–1.01 [0.94]:–1.02 [2.91]–1.09 [1.58]: –0.94 [1.26]
GH peak (ng/mL)1.83 [3.41]: 1.49 [1.79]5.07 [8.34]: 2.04 [2.04]1.52 [1.92]:0.97 [1.34]3.01 [3.46]: 1.35 [1.55]4.01 [9.16]:0.58 [0.90]1.10 [1.87]: 0.74 [0.77]
Waist circumference (cm)98.16 [16.63]: 103.00 [13.77]97.32[14.41]:102.90[12.04]92.21 [20.64]:106.5 [13.86]94.60 [14.51]:100.70 [14.62]93.00 [7.78]:114.00 [11.14]92.38 [15.95]:91.30 [9.37]
BMI (kg/m2)28.85 [6.63]: 29.47 [5.50]28.93 [5.84]: 28.51 [4.94]27.64 [6.77]:28.79 [4.84]29.62 [8.16]: 29.65 [5.92]29.35 [6.85]:31.90 [5.30]29.98 [9.86]:25.62 [4.66]
Average baseline GH dose (mg/kg/day)0.23 [0.16]: 0.24 [0.15]0.17 [0.13]: 0.16 [0.12]0.30 [0.15]:0.27 [0.21]0.28 [0.10]: 0.29 [0.15]0.31 [0.19]:0.25 [0.07]0.24 [0.20]: 0.26 [0.21]
Baseline values, mean [SD] for females:males unless shown as N or %.

Conclusions: This report on adult patients enrolled in NordiNet IOS revealed variations in baseline characteristics, suggesting that national diagnostic and clinical characteristics may affect the country-specific profiles of GHD in adults.

Article tools

My recent searches

No recent searches.